The Global Cell Line Development Market size was valued at USD 6.74 billion in 2021 and is projected to reach USD 12.09 billion by 2028, growing at a CAGR of 8.7% from 2022 to 2028.
The process of developing repeatable and stable cell lines for use in drug discovery, fundamental research, and biopharmaceutical production is what the cell line development market is all about. There are several steps involved in developing a cell line, such as isolating the cells, dividing them, characterizing them, and choosing high-yielding clones. To achieve desired traits and performance, these methods frequently make use of cutting edge techniques like genetic engineering, gene editing, and cell culture optimization. Academic institutions, bioprocessing facilities, biotechnology businesses, and contract research organizations (CROs) are important market players. The growing need for biologics, growing funding for drug discovery, and developments in cell line engineering methods are some of the factors propelling the market's expansion.
Top Key Players Covered in Cell Line Development Market
GE Healthcare, Sartorious AG, Corning Inc., WuXi AppTec Inc., Selexis SA, Sigma-Aldrich Corporation, Lonza Group AG, Sartorius, Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Promega Corporation, Beckman Coulter Inc., European Collection of Cell Cultures, and Other Major Players.
Receive Your Sample Report Without Spending!
https://introspectivemarketresearch.com/request/16126
Introspective Market Research specializes in delivering comprehensive market research studies that offer valuable insights and strategic guidance to businesses worldwide. With a focus on reliability and accuracy, our reports empower informed decision-making.
An in-depth examination of the overall Cell Line Development industry is done to provide this market report encompassing all essential market fundamentals. Our findings are built upon a solid foundation, drawing from a wide range of primary and secondary sources. To further enhance the comprehensiveness of our evaluation, we employ industry-standard tools such as Porter's Five Forces Analysis, SWOT Analysis, and Price Trend Analysis.
Segmentation Analysis of the Cell Line Development Market
By Product
- Equipment
- Reagents & Media
- Accessories & Consumables
By Source
- Mammalian
- Non-Mammalian
By Cell Line Type
- Recombinant Cell Lines
- Hybridomas
- Continuous Cell Lines
- Primary Cell Lines
By Application
- Bioproduction
- Drug Discovery
- Toxicity Testing
- Tissue Engineering
- Research
Need a Customized Report? Let's Talk!
https://introspectivemarketresearch.com/custom-research/16126
Opportunities:
Technological Advancements to Enhance the Manufacturing Process of Cell Lines
The revolutionary techniques known as Cell Line Engineering (CLE) and 3D cell culture include taking primary human or animal cells from basic tissues, cultivating them in three dimensions using selective conditions, and causing the cells to aggregate into spheres called spheroids. 3D cell culture growth conditions comprise a variety of raw materials together referred to as scaffolds. CLE is a cutting-edge technology that enables companies to create cell lines with CRISPR goods. Using a wide range of currently existing cell lines, Thermo Fisher Scientific is creating new cell lines in accordance with the needs for research projects required by their partnering clients. In addition to removing contaminants and uncontrollably occurring mutations, this increases the relevance of cancer cell research, artificial organ growth, and novel treatments to living human tissues.
By Region
- North America (US, Canada, Mexico)
- Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
- Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
- Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)
- Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
- South America (Brazil, Argentina, Rest of SA)
Key Industry Developments in Cell Line Development Market
In September 2022, Sartorius, a life science company, completed the acquisition of Albumedix Ltd. through its French-listed subsidiary Sartorius Stedim Biotech. Albumedix, based in Nottingham, UK, is a market leader in recombinant albumin-based solutions.
In July 2022, Granite Bio and ProBioGen joined forces to provide GMP manufacturing and cell line development services. Granite Bio's lead candidate for the treatment of autoimmune and specific cancer indications is a novel monoclonal antibody.
In January 2021, Thermo Fisher Scientific created a novel medium for the development and expansion of human T lymphocytes (T-cells) for cell therapy developers employing allogeneic workflows. The Gibco CTS OpTmizer Pro Serum-Free Media (SFM) is a first-of-its-kind media solution that addresses the metabolism of healthy donor cells, making it ideal for use in the creation of allogeneic, off-the-shelf cell treatments.
Seize the Moment - Purchase Today!
https://introspectivemarketresearch.com/checkout/?user=1&_sid=16126
About us:
Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to assist our clients grow and have a successful impact on the market. Our team at IMR is ready to assist our clients flourish their business by offering strategies to gain success and monopoly in their respective fields. We are a global market research company, specialized in using big data and advanced analytics to show the bigger picture of the market trends. We help our clients to think differently and build better tomorrow for all of us. We are a technology-driven research company, we analyze extremely large sets of data to discover deeper insights and provide conclusive consulting. We not only provide intelligence solutions, but we help our clients in how they can achieve their goals.
Contact us:
Introspective Market Research
3001 S King Drive,
Chicago, Illinois
60616 USA
Ph no: +1 773 382 1049
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek